Lou Lieto
Partner
-
Chair of the Patents and Innovations Department
Lou has decades of experience advising biotechnology, pharmaceutical, and life science clients on all aspects of patent law and related business matters.
-
Represents Life Sciences Innovators
Lou works with innovators engaged in highly technical fields, including CRISPR, cell therapy, immunotherapeutics, medical devices, pharmaceuticals, stem cells, biofuels, regenerative medicine, and transgenic animals. Prior to joining the firm, Lou was a patent examiner at the USPTO.
-
Designed and Implemented IP Strategy for Multiple Companies with Drugs in Active Clinical Trials
Curemark, Direct Biologics, BioNTech, Marengo Therapeutics, Myeloid Therapeutics, ONL Therapeutics, Prime Medicine, Skyhawk Therapeutics, Stoke Therapeutics, and TCR2 Therapeutics.
-
Extensive Experience Representing Investors and Companies in Financings and M&A
• Anterra Capital, Apple Tree Partners, F-Prime Capital, Flagship Pioneering, Newpath Partners, Novo Ventures, Oxford Science Enterprises, RTW Investments, Samsara Biocapital, SR One, UPMC Enterprises, Venrock, Vida Ventures, and other venture and investment funds in IP diligence matters.
• Have supported more than 100 clients undergoing IP diligence for a venture round of investment. • Aileron Therapeutics, Beam Therapeutics, BioNtech, Cargo Therapeutics, Graphite Bio, Neon Therapeutics, Precigen, Prime Medicine, Recursion Pharmaceuticals, Stoke Therapeutics, and TCR2 Therapeutics on IP matters related to their public offerings.
• 4D Pharma on IP matters related to their cross-border merger into a SPAC and NASDAQ listing.
• B-Mogen Biotechnologies, CellPoint, Delinia, Future Health Works, Midori, MiroBio, Neon Therapeutics, NeuroCycle Therapeutics, Totient, each leading to an acquisition by a major biotech company.
Dr. Louis D. Lieto is the leader of the patents and innovations department at Wilson Sonsini Goodrich & Rosati and is a partner in the firm’s Boston and Washington, D.C., offices. Lou advises biotechnology and pharmaceutical companies on strategic patent counseling, global patent portfolio development and management, and IP counseling for M&A and capital markets in complex life science fields.
Lou received his Ph.D. from the University of Kentucky, where he focused on characterizing the molecular and genetic basis of hereditary disease. Subsequently, Lou completed his postdoctoral fellowship in immunology at the National Institute of Allergy and Infectious Diseases (NIAID).
Prior to joining Wilson Sonsini, Lou was a patent examiner at the U.S. Patent and Trademark Office where he examined applications for inventions encompassing proteins, DNA vectors, nucleic acid vaccines, immune cell therapy, stem cell therapy, transgenic animals, and gene therapy.
Experience
Dr. Louis D. Lieto is the leader of the patents and innovations department at Wilson Sonsini Goodrich & Rosati and is a partner in the firm’s Boston and Washington, D.C., offices. Lou advises biotechnology and pharmaceutical companies on strategic patent counseling, global patent portfolio development and management, and IP counseling for M&A and capital markets in complex life science fields.
Lou received his Ph.D. from the University of Kentucky, where he focused on characterizing the molecular and genetic basis of hereditary disease. Subsequently, Lou completed his postdoctoral fellowship in immunology at the National Institute of Allergy and Infectious Diseases (NIAID).
Prior to joining Wilson Sonsini, Lou was a patent examiner at the U.S. Patent and Trademark Office where he examined applications for inventions encompassing proteins, DNA vectors, nucleic acid vaccines, immune cell therapy, stem cell therapy, transgenic animals, and gene therapy.
Education
- J.D., The George Washington University Law SchoolWith Honors
- Ph.D., Veterinary Science, University of KentuckyAuthored dissertation titled "The Genetic Basis of Epitheliogenesis Imperfecta in Equus caballus"
- B.S., Ecology and Evolutionary Biology, University of RochesterMinor in Political Science
Associations and Memberships
- American Academy of Allergy, Asthma and Immunology
- American Association of Immunologists
- American Intellectual Property Law Association
- International Society for Animal Genetics
Honors
- Recognized as a “Distinguished Leader” in Law.com’s 2024 New England Legal Awards
- Recognized in the Massachusetts Life Sciences category in the 2025-2026 editions of Chambers USA
Admissions
- Bar of the District of Columbia
- State Bar of Massachusetts
- State Bar of New Hampshire
- U.S. District Court for the District of New Hampshire
- U.S. Patent and Trademark Office
Credentials
Education
- J.D., The George Washington University Law SchoolWith Honors
- Ph.D., Veterinary Science, University of KentuckyAuthored dissertation titled "The Genetic Basis of Epitheliogenesis Imperfecta in Equus caballus"
- B.S., Ecology and Evolutionary Biology, University of RochesterMinor in Political Science
Associations and Memberships
- American Academy of Allergy, Asthma and Immunology
- American Association of Immunologists
- American Intellectual Property Law Association
- International Society for Animal Genetics
Honors
- Recognized as a “Distinguished Leader” in Law.com’s 2024 New England Legal Awards
- Recognized in the Massachusetts Life Sciences category in the 2025-2026 editions of Chambers USA
Admissions
- Bar of the District of Columbia
- State Bar of Massachusetts
- State Bar of New Hampshire
- U.S. District Court for the District of New Hampshire
- U.S. Patent and Trademark Office
Select Matters
- ONL Therapeutics on $65 million Series D
- eGenesis on $191 million Series D
- Amber Therapeutics on $100 million Series A
- Verona Pharma on its approval of Ohtuvayre by the FDA
- Ahren, OMX Ventures, +ND Capital and Fine Structures Ventures on Constructive Bio’s $58 million Series A
- Ochre Bio on License Agreement with GSK
- Stoke Therapeutics on IP matters related to $125 million upsized public offering
- Prime Medicine on IP matters related to $161 million upsized public offering
- Arena BioWorks on matters related to launch
- CARGO Therapeutics on IP matters related to $281 million initial public offering
- Chroma Medicine on $135 million Series B
- Amber Therapeutics on their acquisition of Bioinduction
- CARGO Therapeutics on $200 million Series A
- Prime Medicine on patent matters related to its $175 million initial public offering
- MiroBio on patent matters related to acquisition by Gilead Sciences
- Marengo Therapeutics in regards to strategic partnership with Ipsen
- Skyhawk Therapeutics, Inc. on collaboration agreement with Sanofi
- MiroBio on $97 million Series B
- CellPoint in its acquisition by Galapagos
- Totient in its acquisition by AbSci
- SR One related to Simcha Therapeutics' $40 million Series B
- Stoke Therapeutics on IP matters related to collaboration with Acadia Pharmaceuticals
- Chroma on $125 million Series A
- GRO Biosciences on $25 million Series A
- Dunad Therapeutics on strategic collaboration with Novartis
- Midori on patent matters related to acquisition by Royal DSM
- Graphite Bio on IP matters related to initial public offering
- Recursion Pharmaceuticals, Inc. on its $501 million initial public offering
- 4D PHarma on its merger with Longevity Acquisition Corporation
- Oxford Science Innovation on patent matters related to Vaccitech's $168 million Series B
- Oxford Science Innovation on IP matters related to Genomics PLC's $30 million funding round
- NeuroCycle Therapeutics in its acquisition by Engrail Therapeutics
- Precigen on IP matters related to its $129.4 million public offering
- TCR² Therapeutics on patent matters related to $140 million public offering
- Myeloid Therapeutics, Inc. on patent matters related to $50 million financing
Matters
Select Matters
- ONL Therapeutics on $65 million Series D
- eGenesis on $191 million Series D
- Amber Therapeutics on $100 million Series A
- Verona Pharma on its approval of Ohtuvayre by the FDA
- Ahren, OMX Ventures, +ND Capital and Fine Structures Ventures on Constructive Bio’s $58 million Series A
- Ochre Bio on License Agreement with GSK
- Stoke Therapeutics on IP matters related to $125 million upsized public offering
- Prime Medicine on IP matters related to $161 million upsized public offering
- Arena BioWorks on matters related to launch
- CARGO Therapeutics on IP matters related to $281 million initial public offering
- Chroma Medicine on $135 million Series B
- Amber Therapeutics on their acquisition of Bioinduction
- CARGO Therapeutics on $200 million Series A
- Prime Medicine on patent matters related to its $175 million initial public offering
- MiroBio on patent matters related to acquisition by Gilead Sciences
- Marengo Therapeutics in regards to strategic partnership with Ipsen
- Skyhawk Therapeutics, Inc. on collaboration agreement with Sanofi
- MiroBio on $97 million Series B
- CellPoint in its acquisition by Galapagos
- Totient in its acquisition by AbSci
- SR One related to Simcha Therapeutics' $40 million Series B
- Stoke Therapeutics on IP matters related to collaboration with Acadia Pharmaceuticals
- Chroma on $125 million Series A
- GRO Biosciences on $25 million Series A
- Dunad Therapeutics on strategic collaboration with Novartis
- Midori on patent matters related to acquisition by Royal DSM
- Graphite Bio on IP matters related to initial public offering
- Recursion Pharmaceuticals, Inc. on its $501 million initial public offering
- 4D PHarma on its merger with Longevity Acquisition Corporation
- Oxford Science Innovation on patent matters related to Vaccitech's $168 million Series B
- Oxford Science Innovation on IP matters related to Genomics PLC's $30 million funding round
- NeuroCycle Therapeutics in its acquisition by Engrail Therapeutics
- Precigen on IP matters related to its $129.4 million public offering
- TCR² Therapeutics on patent matters related to $140 million public offering
- Myeloid Therapeutics, Inc. on patent matters related to $50 million financing
Select Publications
- Co-author with V. Norviel, D. Hoffmeister, G. Ravitz, J. Ravitz, C. Andres, and R. Watkins, "Citizen Petitions are Crucial in Managing A Drug’s Life Cycle," Law360, November 8, 2019
- Co-author, "The Serious and Immense Impact of a Medical Device Hack," Law360, January 12, 2017
- Co-author, Brief for amici curiae Amarantus Bioscience Holdings, Inc., Exo Incubator, Inc., and Michael Heltzen in support of petitioner, Sequenom, Inc. v. Ariosa Diagnostics, Inc., et al., On Petition for a Writ of Certiorari to the U.S. Supreme Court, No. 15-1182
- Co-author, Brief for amici curiae Population Diagnostics, Inc., Avant Diagnostics, Inc., Personalis, Inc., Linda Bruzzone, and Erin Marie Mading in support of petitioner, Sequenom, Inc. v. Ariosa Diagnostics, Inc., et al., On Petition for a Writ of Certiorari to the U.S. Supreme Court, No. 15-1182
- Co-author, "FDA's Proposed Rules to Address Inaccurate Orange Book Use Codes May Shorten Approval Timelines for Select 505(b)(2) and Generic Drugs," Generic Pharma 2.0, July 15, 2015
- Co-author with D.M. Hoffmeister, V. Norviel, T.J. Noh, M.C. Easterday, P. Girinath, and C. Andres, "Reflections on the Remarkable Rise of Orphan Drugs," Law360, January 28, 2015
- Co-author with C. Andres, V. Norviel, E. Kepplinger, J. Chambers, and C. McAndrew, "Strategies for Maximizing Patent Claim Scope and Patent Protection for Diagnostic Method Claims in the Wake of Mayo v. Prometheus," The Life Sciences Report, Wilson Sonsini Goodrich & Rosati, Spring 2013
- Co-author with V. Norviel, "Fast or Slow? Strategies to Speed Up the Patent Process Among Worldwide Patent Offices," The Intellectual Property Strategist, Vol. 17, No. 4, January 2011
- Co-author with F. Borrego, K. Maasho, D. West, and J.E. Coligan, "The Human CD94 Gene Codes for Multiple, Expressible Transcripts including a New Partner of NKG2A/B," 7 Genes and Immunity 36-43, 2006
- Co-author with A.I. Marusina, D.K. Kim, F. Borrego, and J.E. Coligan, "GATA-3 is an important transcription factor for regulating human NKG2A gene expression," 19 Federation of American Societies for Experimental Biology Journal A17-A17 Part I Supplement S, 2005
- Co-author with F. Borrego and J.E. Coligan, "CD94 1A/1B: A Window Opens into NK Cell Development," 106 Blood 3338-9, 2005
- Co-author with A.I. Marusina, D.K. Kim, F. Borrego, and J.E. Coligan, "GATA-3 Is an Important Transcription Factor for Regulating Human NKG2A Gene Expression," 174 Journal of Immunology 2152-9, 2005
- Co-author with T.W. Swerczek and E.G. Cothran, "Developmental Defects of Enamel in American Saddlebred Foals with Epitheliogenesis Imperfecta," 24 Journal of Equine Veterinary Science 1-5, 2004
- Co-author with F. Borrego, C.H. You, and J.E. Coligan, "Human CD94 Gene Expression: Dual Promoters that Differ in Responsiveness to IL-2 or IL-15 and Bind STAT5A and STAT5B," 17 Federation of American Societies for Experimental Biology Journal 556.8, 2004
- Co-author with A.I. Marusina, D.K. Kim, F. Borrego, and J.E. Coligan, "GATA-3 Is an Important Transcription Factor for Regulating NKG2A Gene Expression," 17 Federation of American Societies for Experimental Biology Journal 556.16, 2004
- Co-author with J.E. Coligan, K. Maasho, and F. Borrego, "Human CD94 gene expression: dual promoters differing in IL-2 responsiveness, alternative transcripts and post transcriptional regulation," 17 Federation of American Societies for Experimental Biology Journal C97-C98 Supplement S, 2003
- Co-author with F. Borrego, C. You, and J.E. Coligan, "Human CD94 Gene Expression: Dual Promoters Differing in Responsiveness to IL-2 or IL-15," 171 Journal of Immunology 5277-5286, 2003
- Co-author with E.G. Cothran, "The Epitheliogenesis Imperfecta Locus Maps to Equine Chromosome 8 in American Saddlebred Horses," 102 Cytogenetics and Genome Research 207-210, 2003
- Co-author with J. Gregan, L. Van Laer, G. Van Camp, and S.E. Kearsey, "A Yeast Model for the Study of Human DFNA5, a Gene Mutated in Non-syndromic Hearing Impairment," 1638 Biochimica et Biophysica Acta 179-186, 2003
- Co-author with F. Borrego, J. Kabat, D.K. Kim, K. Maasho, J. Peña, R. Solana, and J.E. Coligan, "Structure and Function of Major Histocompatibility Complex (MHC) Class I Specific Receptors Expressed on Human Natural Killer (NK) Cells," 38 Molecular Immunology 637-660, 2002
- Co-author with D.K. Kim, F. Borrego, and J.E. Coligan, "Characterization of the Human NKG2A Promoter, 16 Federation of American Societies for Experimental Biology Journal A694-A694 Part 1, 2002
- Co-author with K. Maasho, F. Borrego, and J.E. Coligan, "Defining the Regulatory Factors Required for CD94 Gene Expression," 16 Federation of American Societies for Experimental Biology Journal A694-A694 Part 1, 2002
- Co-author with T.W. Swerczek and E.G. Cothran, "Equine Epitheliogenesis Imperfecta in Two American Saddlebred Foals Is a Lamina Lucida Defect," 39 Veterinary Pathology 576-580, 2002
- Co-author with E.G. Cothran, "Characterization of Expressed Sequence Tags Generated from Skin cDNA Clones of Equus caballus by 5 Prime Sequencing," 12 Animal Biotechnology 87-97, 2001
- Co-author with N. El Hage and B. Stevenson, "Stability of Antigen-Encoding erp Loci in Borrelia burgdorfei Reisolated from Chronically Infected Immunocompetent Mice," 67 Infection and Immunity 3146-3150, 1999
- Co-author with E.G. Cothran and D.P. Sponenberg, "Molecular Characterization and Genetic Analysis of Black Coat Color in the Horse," 29 (supp. 1) Animal Genetics 57, 1998
Insights
Select Publications
- Co-author with V. Norviel, D. Hoffmeister, G. Ravitz, J. Ravitz, C. Andres, and R. Watkins, "Citizen Petitions are Crucial in Managing A Drug’s Life Cycle," Law360, November 8, 2019
- Co-author, "The Serious and Immense Impact of a Medical Device Hack," Law360, January 12, 2017
- Co-author, Brief for amici curiae Amarantus Bioscience Holdings, Inc., Exo Incubator, Inc., and Michael Heltzen in support of petitioner, Sequenom, Inc. v. Ariosa Diagnostics, Inc., et al., On Petition for a Writ of Certiorari to the U.S. Supreme Court, No. 15-1182
- Co-author, Brief for amici curiae Population Diagnostics, Inc., Avant Diagnostics, Inc., Personalis, Inc., Linda Bruzzone, and Erin Marie Mading in support of petitioner, Sequenom, Inc. v. Ariosa Diagnostics, Inc., et al., On Petition for a Writ of Certiorari to the U.S. Supreme Court, No. 15-1182
- Co-author, "FDA's Proposed Rules to Address Inaccurate Orange Book Use Codes May Shorten Approval Timelines for Select 505(b)(2) and Generic Drugs," Generic Pharma 2.0, July 15, 2015
- Co-author with D.M. Hoffmeister, V. Norviel, T.J. Noh, M.C. Easterday, P. Girinath, and C. Andres, "Reflections on the Remarkable Rise of Orphan Drugs," Law360, January 28, 2015
- Co-author with C. Andres, V. Norviel, E. Kepplinger, J. Chambers, and C. McAndrew, "Strategies for Maximizing Patent Claim Scope and Patent Protection for Diagnostic Method Claims in the Wake of Mayo v. Prometheus," The Life Sciences Report, Wilson Sonsini Goodrich & Rosati, Spring 2013
- Co-author with V. Norviel, "Fast or Slow? Strategies to Speed Up the Patent Process Among Worldwide Patent Offices," The Intellectual Property Strategist, Vol. 17, No. 4, January 2011
- Co-author with F. Borrego, K. Maasho, D. West, and J.E. Coligan, "The Human CD94 Gene Codes for Multiple, Expressible Transcripts including a New Partner of NKG2A/B," 7 Genes and Immunity 36-43, 2006
- Co-author with A.I. Marusina, D.K. Kim, F. Borrego, and J.E. Coligan, "GATA-3 is an important transcription factor for regulating human NKG2A gene expression," 19 Federation of American Societies for Experimental Biology Journal A17-A17 Part I Supplement S, 2005
- Co-author with F. Borrego and J.E. Coligan, "CD94 1A/1B: A Window Opens into NK Cell Development," 106 Blood 3338-9, 2005
- Co-author with A.I. Marusina, D.K. Kim, F. Borrego, and J.E. Coligan, "GATA-3 Is an Important Transcription Factor for Regulating Human NKG2A Gene Expression," 174 Journal of Immunology 2152-9, 2005
- Co-author with T.W. Swerczek and E.G. Cothran, "Developmental Defects of Enamel in American Saddlebred Foals with Epitheliogenesis Imperfecta," 24 Journal of Equine Veterinary Science 1-5, 2004
- Co-author with F. Borrego, C.H. You, and J.E. Coligan, "Human CD94 Gene Expression: Dual Promoters that Differ in Responsiveness to IL-2 or IL-15 and Bind STAT5A and STAT5B," 17 Federation of American Societies for Experimental Biology Journal 556.8, 2004
- Co-author with A.I. Marusina, D.K. Kim, F. Borrego, and J.E. Coligan, "GATA-3 Is an Important Transcription Factor for Regulating NKG2A Gene Expression," 17 Federation of American Societies for Experimental Biology Journal 556.16, 2004
- Co-author with J.E. Coligan, K. Maasho, and F. Borrego, "Human CD94 gene expression: dual promoters differing in IL-2 responsiveness, alternative transcripts and post transcriptional regulation," 17 Federation of American Societies for Experimental Biology Journal C97-C98 Supplement S, 2003
- Co-author with F. Borrego, C. You, and J.E. Coligan, "Human CD94 Gene Expression: Dual Promoters Differing in Responsiveness to IL-2 or IL-15," 171 Journal of Immunology 5277-5286, 2003
- Co-author with E.G. Cothran, "The Epitheliogenesis Imperfecta Locus Maps to Equine Chromosome 8 in American Saddlebred Horses," 102 Cytogenetics and Genome Research 207-210, 2003
- Co-author with J. Gregan, L. Van Laer, G. Van Camp, and S.E. Kearsey, "A Yeast Model for the Study of Human DFNA5, a Gene Mutated in Non-syndromic Hearing Impairment," 1638 Biochimica et Biophysica Acta 179-186, 2003
- Co-author with F. Borrego, J. Kabat, D.K. Kim, K. Maasho, J. Peña, R. Solana, and J.E. Coligan, "Structure and Function of Major Histocompatibility Complex (MHC) Class I Specific Receptors Expressed on Human Natural Killer (NK) Cells," 38 Molecular Immunology 637-660, 2002
- Co-author with D.K. Kim, F. Borrego, and J.E. Coligan, "Characterization of the Human NKG2A Promoter, 16 Federation of American Societies for Experimental Biology Journal A694-A694 Part 1, 2002
- Co-author with K. Maasho, F. Borrego, and J.E. Coligan, "Defining the Regulatory Factors Required for CD94 Gene Expression," 16 Federation of American Societies for Experimental Biology Journal A694-A694 Part 1, 2002
- Co-author with T.W. Swerczek and E.G. Cothran, "Equine Epitheliogenesis Imperfecta in Two American Saddlebred Foals Is a Lamina Lucida Defect," 39 Veterinary Pathology 576-580, 2002
- Co-author with E.G. Cothran, "Characterization of Expressed Sequence Tags Generated from Skin cDNA Clones of Equus caballus by 5 Prime Sequencing," 12 Animal Biotechnology 87-97, 2001
- Co-author with N. El Hage and B. Stevenson, "Stability of Antigen-Encoding erp Loci in Borrelia burgdorfei Reisolated from Chronically Infected Immunocompetent Mice," 67 Infection and Immunity 3146-3150, 1999
- Co-author with E.G. Cothran and D.P. Sponenberg, "Molecular Characterization and Genetic Analysis of Black Coat Color in the Horse," 29 (supp. 1) Animal Genetics 57, 1998
Biological Sciences and Biotechnology
- Antibody
- Antigen presentation
- Biochemical assays
- Biochemistry
- Bioconjugation
- Biologics
- Cancer biology
- Cancer therapeutics
- CAR-T cells
- Cell biology
- Cell culture products
- Cell therapy
- Cellular biology
- Cellular immunology
- Epigenetics
- Genetics
- Genomics
- Glycobiology
- Host-pathogen interactions
- Immuno-oncology
- Immunobiology
- Immunology
- Metabolomics
- Microbiology
- MicroRNA (miRNA) research
- Molecular biology
- Molecular genetics
- Neurobiology
- PCR
- Proteomics
- Stem cell biology
- T and B cell biology
- T cell biology
- T cell immunology
- Virology
Therapeutics and Drug Discovery
- Antimicrobial agents
- Biosimilars
- CRISPR
- Drug conjugates
- Drug conjugates based drug discovery
- Drug delivery
- Gene editing
- Gene therapy
- Immunotherapy targets
- Neuropharmacology
- Peptide therapeutics
- Pharmacodynamics
- Pharmacogenomics
- Pharmacokinetics
- Pharmacology
- RNA interference (RNAi)
- Small molecule synthesis
- Small molecules
- Vaccines
Diagnostics and Medical Devices
- Biomedical devices
- Biomedical engineering
- Biosensors
- Diagnostics
- Medical devices
- miRNA detection
- Point-of-care testing (POCT)
- Wearable analyte sensors
Chemistry and Material Science
- Chemistry
- Green chemistry
- Organic chemistry
- Peptidomimetics
- Polymorph
- Process chemistry
- Protein engineering
- Protein folding
- Supramolecular chemistry
Genomics and Data Analysis
- Bioinformatics algorithms
- Computational biology
- Functional genomics
- Next-generation sequencing
- rDNA
- Sequencing
- shRNA
- Single-cell sequencing
Miscellaneous
- Cancer
- COVID 19
- Engineered foods
- Fluorescence microscopy
- Food science
- Formulations
- Health economics and outcomes research (HEOR)
- Human factors engineering
- Infectious diseases
- Ophthalmology
Technical Fluency
Biological Sciences and Biotechnology
- Antibody
- Antigen presentation
- Biochemical assays
- Biochemistry
- Bioconjugation
- Biologics
- Cancer biology
- Cancer therapeutics
- CAR-T cells
- Cell biology
- Cell culture products
- Cell therapy
- Cellular biology
- Cellular immunology
- Epigenetics
- Genetics
- Genomics
- Glycobiology
- Host-pathogen interactions
- Immuno-oncology
- Immunobiology
- Immunology
- Metabolomics
- Microbiology
- MicroRNA (miRNA) research
- Molecular biology
- Molecular genetics
- Neurobiology
- PCR
- Proteomics
- Stem cell biology
- T and B cell biology
- T cell biology
- T cell immunology
- Virology
Therapeutics and Drug Discovery
- Antimicrobial agents
- Biosimilars
- CRISPR
- Drug conjugates
- Drug conjugates based drug discovery
- Drug delivery
- Gene editing
- Gene therapy
- Immunotherapy targets
- Neuropharmacology
- Peptide therapeutics
- Pharmacodynamics
- Pharmacogenomics
- Pharmacokinetics
- Pharmacology
- RNA interference (RNAi)
- Small molecule synthesis
- Small molecules
- Vaccines
Diagnostics and Medical Devices
- Biomedical devices
- Biomedical engineering
- Biosensors
- Diagnostics
- Medical devices
- miRNA detection
- Point-of-care testing (POCT)
- Wearable analyte sensors
Chemistry and Material Science
- Chemistry
- Green chemistry
- Organic chemistry
- Peptidomimetics
- Polymorph
- Process chemistry
- Protein engineering
- Protein folding
- Supramolecular chemistry
Genomics and Data Analysis
- Bioinformatics algorithms
- Computational biology
- Functional genomics
- Next-generation sequencing
- rDNA
- Sequencing
- shRNA
- Single-cell sequencing
Miscellaneous
- Cancer
- COVID 19
- Engineered foods
- Fluorescence microscopy
- Food science
- Formulations
- Health economics and outcomes research (HEOR)
- Human factors engineering
- Infectious diseases
- Ophthalmology
Recent Insights
News Articles
Wilson Sonsini Practices, Attorneys Recognized in 2026 Chambers USA Guide
The 2026 Chambers USA guide has recognized Wilson Sonsini Goodrich & Rosati as a leading law firm in 44 geography-specific practice categories and named 87 Wilson Sonsini attorneys among the best in their fields. This year, the firm received four new practice area rankings, including in the nationwide National Security and Capital Markets: Convertible Debt categories, and three improved practice area rankings.
Learn More
News Articles
Wilson Sonsini Joins Nucleate Leadership Council as Co-Founding Member
On June 1, 2026, Nucleate, a nonprofit organization dedicated to empowering the next generation of biotech leaders, announced the launch of the Nucleate Leadership Council (NLC), a new community of biotech leaders and disruptors committed to supporting the next generation of scientists and entrepreneurs. Wilson Sonsini is proud to join the NLC as a co-founding member.
Learn More
Recent Events
Affiliated Programs
NextGen VC Forum – Boston
Curated by Wilson Sonsini's Michael Hostetler and Dan Koeppen, LaunchBio’s NextGen VC Forum is the premiere event for venture capital associates to expand their skills and expertise while growing their network. The half-day forum includes a networking breakfast, three one-hour sessions and lunch. Attendance at NextGen VC Forum is by invitation only.
Learn More
WSGR Events
College for Clients Series: IP Protection and Commercialization
It is critical for companies to understand how to best manage and protect their intellectual property. To support our clients' in-house counsel, business development VPs, CTOs, CIOs, contracts administrators, and others involved in IP-related issues, Wilson Sonsini is hosting a webinar that will provide practical tips and materials on best practices for preserving value and protecting against risk throughout the life cycle of a company.
Learn More
- Privacy Policy
- Terms of Use
- Accessibility
Copyright © 2026 Wilson Sonsini Goodrich & Rosati. All Rights Reserved.